MedTrace Logo

A Phase I Study to Evaluate the Safety and Drug Allergy of HLB3-002 in Healthy Volunteers

NCT06713317 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 243

Last updated 2025-07-01

No results posted yet for this study

Summary

Part I) multi-center, randomized, double-blind, placebo controlled

Part II) multi-center, randomized, double-blind, placebo controlled

Conditions

  • Healthy

Interventions

DRUG

HLB3-002

Recombinant Hyaluronidase

DRUG

0.9% NaCl

0.9% Normal saline

Sponsors & Collaborators

  • Huonslab Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Donghoon Lee, MD, Ph.D · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-02
Primary Completion
2025-06-27
Completion
2025-06-27

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06713317 on ClinicalTrials.gov